Contineum Therapeutics, Inc. Class A (CTNM) AI Stock Analysis

• Market Cap: $429.59M
• Dividend Yield: N/A
• Average Volume (3M): 170.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: -100.71%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 30,446,112
• 10 Day Avg. Volume: 105,448
• 30 Day Avg. Volume: 170,880
• PEG Ratio: 0.02
• Price to Book (P/B): 1.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.50
• Enterprise Value/Market Cap: -0.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 418.29
• Enterprise Value/Ebitda: 1.09
• 1Y Price Target: $18.60
• Price Target Upside: 58.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $12.00 ▲(2.04% Upside)

Overall score reflects weak current fundamentals (no revenue, widening losses and cash burn) partially mitigated by a low-debt balance sheet. Technicals are mildly supportive with price above major moving averages, but momentum is not fully confirmed. A negative clinical trial readout and loss-driven valuation metrics further weigh on the score.

Positive Factors

Balance Sheet Health

Low leverage provides financial flexibility, allowing the company to invest in R&D and withstand periods of cash burn without immediate financial distress.

Pipeline Development

Advancing PIPE-791 into Phase 2 for IPF demonstrates ongoing commitment to pipeline development, potentially leading to new revenue streams if successful.

R&D Investment

Increased R&D investment signals a focus on innovation and long-term growth, which is crucial for maintaining competitive advantage in biotechnology.

Negative Factors

Cash Burn

Significant cash burn increases reliance on external financing, which can be risky if market conditions change or funding becomes less accessible.

Clinical Trial Setback

Failure to meet trial endpoints raises clinical and pipeline risk, potentially delaying product development and impacting future revenue potential.

Revenue and Profitability

Lack of revenue and widening losses indicate ongoing challenges in achieving commercial success, increasing financial risk and execution challenges.

Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model

Company Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

How the Company Makes Money

Contineum Therapeutics, Inc. generates revenue through a combination of product sales, licensing agreements, and strategic collaborations. The company commercializes its proprietary therapies once they receive regulatory approval and actively engages in partnerships with other pharmaceutical companies to co-develop and co-market its drug candidates. Additionally, Contineum Therapeutics may receive milestone payments and royalties from licensing its technology and products to partners. The company's revenue model is also supported by government grants and funding from research institutions that contribute to its research and development efforts.

Contineum Therapeutics, Inc. Class A Financial Statement Overview

Summary

Contineum Therapeutics, Inc. faces significant financial challenges, particularly in generating revenue and maintaining profitability. While debt reduction and strong cash reserves are positive, the negative equity and cash flow issues require strategic focus to ensure long-term viability. The company's financial health is under pressure, demanding careful management and potential restructuring efforts.

Income Statement

Contineum Therapeutics, Inc. shows a challenging income statement with no revenue in the latest period, resulting in negative profitability metrics. The company has seen significant fluctuations, with past revenue and subsequent losses. The lack of revenue growth and negative margins indicate significant financial challenges in generating sales or reducing costs.

Balance Sheet

The balance sheet presents a mixed picture. On the positive side, the company has a strong cash position and a significant reduction in total debt, indicating improved financial stability. However, negative stockholders' equity remains a concern, suggesting ongoing financial risks and potential insolvency issues.

Cash Flow

Cash flow analysis reveals a problematic situation with negative operating and free cash flows, although there is a notable improvement in cash generated from financing activities. The negative free cash flow to net income ratio highlights a lack of operational sustainability, posing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	50.00M	0.00	0.00
Gross Profit	-160.00K	-258.00K	50.00M	-329.00K	0.00
EBITDA	-61.19M	-42.00M	23.57M	-23.54M	-28.34M
Net Income	-59.39M	-42.26M	22.72M	-24.25M	-29.00M
Balance Sheet
Total Assets	190.85M	212.85M	130.39M	50.64M	70.52M
Cash, Cash Equivalents and Short-Term Investments	182.41M	204.76M	125.19M	47.24M	69.00M
Total Debt	5.49M	6.26M	193.19M	5.85M	4.91M
Total Liabilities	10.38M	14.78M	198.32M	11.37M	8.93M
Stockholders Equity	180.47M	198.07M	-67.94M	39.27M	61.59M
Cash Flow
Free Cash Flow	-52.83M	-33.36M	18.93M	-20.24M	-26.43M
Operating Cash Flow	-52.47M	-32.84M	19.35M	-20.12M	-26.27M
Investing Cash Flow	34.35M	-69.74M	-65.57M	22.30M	-64.97M
Financing Cash Flow	19.86M	109.00M	56.18M	-1.24M	79.84M

Contineum Therapeutics, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.76
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Positive. The current price of 11.76 is above the 20-day moving average (MA) of 11.07, above the 50-day MA of 11.18, and above the 200-day MA of 8.07, indicating a bullish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 56.65 is Neutral, neither overbought nor oversold. The STOCH value of 60.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTNM.

Contineum Therapeutics, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	57 Neutral	$1.35B	-13.78	-107.79%	―	-52.08%	-69.35%
ENGN	55 Neutral	$609.56M	-3.97	-53.28%	―	―	-52.86%
IMRX	52 Neutral	$286.04M	-2.48	-43.75%	―	―	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRTS	51 Neutral	$639.48M	-14.38	-54.38%	―	―	-22.82%
CTNM	50 Neutral	$429.59M	-5.21	-30.40%	―	―	-100.71%
TVRD	38 Underperform	$43.44M	-0.47	-97.61%	―	-53.67%	86.75%

Contineum Therapeutics, Inc. Class A Corporate Events

Contineum Therapeutics Submits Phase 2 Trial for PIPE-791

On December 8, 2025, Contineum Therapeutics, Inc. Class A announced the submission of its global Phase 2 clinical trial details for PIPE-791, aimed at treating idiopathic pulmonary fibrosis (IPF), to the ClinicalTrials.gov Protocol Registration and Results System. The trial, which is expected to enroll approximately 324 subjects globally, will evaluate the safety, tolerability, and efficacy of PIPE-791 over a 26-week period. The company plans to complete the trial by June 2028, with the trial design informed by previous regulatory engagement and Phase 1 clinical trials. This initiative highlights the company’s commitment to advancing treatment options for IPF, although it faces substantial risks and uncertainties related to clinical drug development, regulatory approvals, and market competition.

The most recent analyst rating on (CTNM) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.

Contineum Therapeutics Reports Phase 2 Trial Results

On November 20, 2025, Contineum Therapeutics reported topline data from its Phase 2 VISTA trial of PIPE-307 for treating relapsing-remitting multiple sclerosis (RRMS). The trial showed that PIPE-307 had an acceptable safety and tolerability profile but did not meet its primary or secondary efficacy endpoints, as no significant change was observed in binocular 2.5% low contrast letter acuity. Despite the disappointing results, Contineum remains committed to developing therapies for inflammatory and fibrotic diseases and plans to present the complete dataset at a future medical meeting.

The most recent analyst rating on (CTNM) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.